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Pulmonary ﬁbrosis is a group of disorders characterized by accumulation of scar tissue in the lung interstitium, resulting in loss
of alveolar function, destruction of normal lung architecture, and respiratory distress. Some types of ﬁbrosis respond to corticos-
teroids, but for many there are no eﬀective treatments. Prognosis varies but can be poor. For example, patients with idiopathic
pulmonary ﬁbrosis (IPF) have a median survival of only 2.9 years. Prognosis may be better in patients with some other types of
pulmonary ﬁbrosis, and there is variability in survival even among individuals with biopsy-proven IPF. Evidence is accumulating
that the peroxisome proliferator-activated receptors (PPARs) play important roles in regulating processes related to ﬁbrogenesis,
including cellular diﬀerentiation, inﬂammation, and wound healing. PPARα agonists, including the hypolidipemic ﬁbrate drugs,
inhibit the production of collagen by hepatic stellate cells and inhibit liver, kidney, and cardiac ﬁbrosis in animal models. In the
mouse model of lung ﬁbrosis induced by bleomycin, a PPARα agonist signiﬁcantly inhibited the ﬁbrotic response, while PPARα
knockout mice developed more serious ﬁbrosis. PPARβ/δ appears to play a critical role in regulating the transition from inﬂam-
mation to wound healing. PPARβ/δ agonists inhibit lung ﬁbroblast proliferation and enhance the antiﬁbrotic properties of PPARγ
agonists. PPARγ ligands oppose the proﬁbrotic eﬀect of TGF-β, which induces diﬀerentiation of ﬁbroblasts to myoﬁbroblasts, a
critical eﬀector cell in ﬁbrosis. PPARγ ligands, including the thiazolidinedione class of antidiabetic drugs, eﬀectively inhibit lung
ﬁbrosis in vitro and in animal models. The clinical availability of potent and selective PPARα and PPARγ agonists should facilitate
rapid development of successful treatment strategies based on current and ongoing research.
Copyright © 2007 Heather F. Lakatos et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Pulmonary ﬁbrosis is a potentially fatal disease character-
ized by accumulation of scar tissue in the lung interstitium,
resulting in loss of alveolar function, destruction of nor-
mal lung architecture, and respiratory distress [1–3]. Known
causesincludeinhalationofdustsandotherparticulatessuch
as silica and asbestos, chemo- and radiation therapy, au-
toimmunity, hypersensitivity pneumonitis, and sarcoidosis
[4, 5]. The idiopathic interstitial pneumonias, as the name
suggests,areagroupofﬁbroticdiseasesofunknownetiology,
the commonest of which is the usual intersitial pneumonitis
(UIP), also called idiopathic pulmonary ﬁbrosis (IPF) [6–8].
Some types of ﬁbrosis respond to corticosteroids but many
are refractory [9–11]. Prognosis is varied, but can be poor.
UIP is considered to be the most severe of the idiopathic in-
terstitial pneumonias. However, there is signiﬁcant variabil-
ity in the natural history of this disease. For example, the
mean survival time after a diagnosis of UIP is less than three
years [12], but there are patients who can survive for much
longer periods of time with much slower (or rarely no) pro-
gression of their lung disease [13]. In contrast, other patients
can develop acute exacerbations of their pulmonary ﬁbrosis
withtherapidonsetofdyspnea,newradiographicabnormal-
ities, respiratory failure, and death in 20%–86% of patients.
Histological examination of their lungs reveals diﬀuse alveo-
lar damage superimposed on a background of UIP [12]. The
etiology of these exacerbations is unclear, but factors includ-
ing infection have been implicated.
At the cellular level, pulmonary ﬁbrosis is character-
ized by proliferation and accumulation of ﬁbroblasts and
scar-forming myoﬁbroblasts in the lung interstitium with
increased synthesis and deposition of extracellular matrix
proteinsincludingcollagenandﬁbronectin[9,14].Although2 PPAR Research
ﬁbroblasts were previously regarded as simple structural
cells, they are now recognized as having important sentinel
and regulatory functions and are a rich source of regula-
tory cytokines and chemokines [15]. Fibroblasts diﬀerentiate
to myoﬁbroblasts after appropriate stimuli, including trans-
forming growth factor (TGF)-β1[ 9, 14, 16]. Myoﬁbrob-
lasts have some of the characteristics of smooth muscle cells,
including contractility and expression of α-smooth muscle
actin (α-SMA) [14, 17, 18]. The diﬀerentiation of ﬁbroblasts
to myoﬁbroblasts, along with increased cellular proliferation
and matrix deposition, leads to the development of ﬁbrob-
lastic foci similar in appearance to the early stages of nor-
mal wound healing. Fibrosis is usually progressive, leading to
destruction of the normal lung architecture [2, 14, 17, 18].
Other organs can develop ﬁbrosis, including the skin, liver,
kidney, and pancreas, and the cellular events and signals are
likely to be similar.
It has been hypothesized that ﬁbrosis is a consequence
of abnormal regulation of wound repair [2, 19, 20]. An in-
juryleadstoacuteinﬂammation,followedbyaninitialrepair
phase in which ﬁbroblasts and myoﬁbroblasts at the injury
site replace damaged tissue with scar tissue. Normally, this
phase of wound repair is self-limiting, with myoﬁbroblasts
eventually undergoing apoptosis, and the scar tissue may
be remodeled and reconstructed as relatively normal func-
tionaltissue.Inﬁbrosis,theﬁbroblastsandmyoﬁbroblastsdo
not undergo apoptosis, but continue to proliferate, resulting
in progressive scarring. The cellular signals involved in the
maintenance of the proﬁbrotic phenotype are unknown, al-
though it is likely that TGF-β is a critical factor [21–24].
2. PPARs AND LUNG DISEASE
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to the nu-
clear hormone receptor family, that function to regulate a
wide range of physiological activities [25]. Three diﬀerent
isoforms of PPARs have been identiﬁed: PPARα (NR1C1),
PPARβ/δ (NUC1; NR1C2), and PPARγ (NR1C3), encoded
by three separate genes. The PPARs and their obligate core-
ceptors,theretinoidXreceptors(RXRs),bindavarietyoflig-
ands. The ligand-activated heterodimeric complexes then in-
duceexpressionoftargetgenescarryingperoxisomeprolifer-
ators response elements (PPREs) in their promoters. PPARα
was ﬁrst identiﬁed as the mediator of the response to per-
oxisome proliferators in rodents [26]. Over the past decade,
PPARs have been implicated as important regulators of var-
ious physiological processes, such as lipid and lipoprotein
metabolism, glucose homeostasis, cellular proliferation, dif-
ferentiation, and apoptosis. PPARα is found in high levels in
liver, kidney, heart, and muscle, whereas PPARβ/δ is ubiq-
uitously expressed [26, 27]. PPARγ is found in two main
isoforms, PPARγ1a n dP P A R γ2, derived from diﬀerent pre-
mRNA splice variants that use diﬀerent transcription start
sites. PPARγ is widely expressed, and has been found in
blood cells, such as macrophages [28], T and B lympho-
cytes [29, 30], and platelets [31], as well as in tissues in-
cluding adipose, colon, spleen, retina, skeletal muscle, liver,
bone marrow, and lung [27]. Within the lung, PPARγ is ex-
pressed by the epithelium, smooth muscle cells, ﬁbroblasts,
endothelium, macrophages, eosinophils, and dendritic cells
[32].
The role of the PPARs in lung disease is not yet clear.
Both PPARα and PPARγ have been localized in lung tis-
sue, including bronchial epithelial cells, alveolar walls, and
alveolar macrophages [27, 32, 33]. A comparison of non-
smokers, smokers with chronic obstructive pulmonary dis-
ease (COPD), and smokers without COPD found no statisti-
cally signiﬁcant diﬀerence in the number of PPARγ-positive
macrophages, but found an increased number of PPARα-
positive alveolar macrophages in smokers with COPD [34].
Sarcoidosis and pulmonary alveolar proteinosis are two
other disorders in which alveolar macrophages are deﬁ-
cient in PPARγ [35].A causal relationship has not been de-
termined, however, treatment of pulmonary alveolar pro-
teinosis with granulocyte-macrophage colony-stimulating
factor (GM-CSF) restores alveolar macrophage PPARγ levels
[36].
There is evidence that the PPARs, particularly PPARα
and PPARγ, play a role in regulating inﬂammation. For ex-
ample, fatty-acid-derived inﬂammatory mediators, includ-
ing prostaglandins and leukotrienes, are ligands for PPARα
and γ [37]. Although the pathogenesis of ﬁbrosis appears to
be distinct from inﬂammation, and many forms of ﬁbrosis
are refractory to anti-inﬂammatory therapies such as corti-
costeroids, recent work has supported the hypothesis that ﬁ-
brosis is a consequence of a dysregulated wound healing pro-
cess with an initial injury and inﬂammatory response. Cer-
tainly, many important inﬂammatory signals and mediators,
particularly TGF-β,T N F - α,a n dI L - 1 β, and prostaglandins,
play key roles in ﬁbrosis [21–24]. This review will discuss re-
cent reports examining the link between PPARs and ﬁbrosis,
and the possibility of using PPAR ligands as antiﬁbrotic ther-
apies. Because the study of PPARs in lung ﬁbrosis is relatively
new, we will also review selected results from ﬁbrotic disease
models in other organs.
3. PPARα
PPARα was originally cloned as the molecular target for
the hypolipidemic ﬁbrate drugs, although arachidonic acid
metabolites (eicosanoids, prostaglandins, and leukotrienes)
are also important ligands [38]. PPARα plays a key role in
lipid metabolism and is highly expressed in tissues involved
in lipid and cholesterol metabolism, including the liver, kid-
ney, and macrophages. PPARα ligands have important anti-
inﬂammatory properties, although some studies have re-
ported proinﬂammatory eﬀects as well [37, 39]. Little is
known about PPARα in lung disease, although other ﬁbro-
sis models implicate PPARα in regulating ﬁbrosis.
Intheliver,thePPARαagonistsfenoﬁbrateandWY14643
dramatically reduced ﬁbrosis in the thioacetamide model
of cirrhosis [40]. N-3 polyunsaturated fatty acid, another
PPARα ligand, reduced hepatic and serum TNF-α levels and
reduced the degree of liver injury in a rat model of non-
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WY14643 reduced the severity of steatohepatitis in C57BL/6
mice fed a methionine- and choline-deﬁcient diet, with re-
ductions in hepatic mRNA levels of collagen alpha 1, tissue
inhibitor of metalloproteinase (TIMP)-1 and TIMP-2, and
matrix metalloproteinase (MMP)-13 [42].
Fenoﬁbrate also attenuated cardiac and vascular ﬁbro-
sis in pressure-overloaded rat hearts, with reductions in
collagen I and III mRNA [43], and inhibited ﬁbrotic left
ventricular remodeling in mineralcorticoid-dependent hy-
pertension [44]. The PPARα agonist gemﬁbrozil attenu-
ated glomerulosclerosis and collagen deposition in diabetic
ApoE-knockout mice [45].
Recent reports have found signiﬁcantly reduced PPARα
mRNA levels in lymphocytes from cystic ﬁbrosis patients
[46], while PPARα knockout mice develop more severe
carageenan-induced pleural inﬂammation [47], suggesting a
connection between diminished PPARα-dependent gene ac-
tivation and disease pathology.
T h er o l eo fP P A R α in lung ﬁbrosis was investigated in
mice using the bleomycin model of lung injury and ﬁ-
brosis. Intratracheal instillation of the antineoplastic agent
bleomycincausesacutelunginﬂammationthatdevelopsinto
severe ﬁbrosis, with proliferation of α-SMA-positive myoﬁ-
broblasts, increased collagen deposition, and loss of normal
alveolar architecture [48, 49]. PPARα-knockout mice treated
with bleomycin developed more severe inﬂammation and
ﬁbrosis than wild-type mice, with increased immunohisto-
chemical detection of TNF-α and IL-1β, increased apoptosis
of interstitial cells, and decreased survival [50]. Treatment of
wild-type mice with the PPARα agonist WY-14643 enhanced
survival and reduced the severity of ﬁbrosis, as well as reduc-
ing the detection of TNF-α and apoptosis by immunohisto-
chemistry. The authors concluded that endogenous PPARα
ligands play an important role in limiting the ﬁbrotic re-
sponse in wild-type mice, and that treatment with PPARα
ligands has potential as an antiﬁbrotic therapy.
As yet, there have been no molecular mechanisms pro-
posed to explain these results. Since bleomycin treatment re-
sults in an acute inﬂammatory response that later resolves
into ﬁbrosis, it is possible that PPARα agonists act to inhibit
ﬁbrosis by moderating the initial inﬂammatory response.
This could be addressed by using a ﬁbrogenic insult that pro-
vokes minimal inﬂammation, such as adenovirus-mediated
overexpression of TGF-β [24].
Interestingly, there is some evidence that the eﬀects
of PPARα agonists are not entirely dependent on PPARα-
dependent transcription [51]. Since the above study did not
report treating PPARα-knockout mice with WY-14643, the
issue of the PPARα dependence or independence of the ef-
fect was not addressed. It should also be noted that WY-
14643 is also a weak PPARγ agonist [52], and PPARγ ago-
nists may have antiﬁbrotic activity as well (discussed below).
One way to investigate the PPARα dependence or indepen-
dence of PPARα agonists would be to study their eﬀects in
PPARα-knockout ﬁbroblasts in vitro and PPARα-knockout
mice in vivo. Studies using additional in vivo models of ﬁ-
brosis (such as thoracic radiation or inhalation of crystalline
silica) should also prove informative.
4. PPARβ/δ
Although little is known about PPARβ/δ in the lung,
PPARβ/δ does play a critical role in wound healing in
the skin. PPARβ/δ expression is upregulated following skin
injury. Further, PPARβ/δ-knockout mice exhibit defective
in vivo wound healing, and keratinocytes from PPARβ/δ-
knockout mice show decreased adhesion and migration in
vitro [53]. It has been suggested that PPARβ/δ is a critical
regulator of the transition from the initial inﬂammatory re-
sponse to the later wound healing program [54].
An intriguing recent study suggested that PPARβ/δ
may be a target of prostacyclin mimetics used in treating
pulmonary hypertension. Treprostinil sodium activated a
PPARβ/δ reportergeneandinhibited proliferationoflungﬁ-
broblasts in vitro. The eﬀect was not seen in lung ﬁbroblasts
from PPARβ/δ-knockout mice, demonstrating that the eﬀect
was dependent on PPARβ/δ and not on the prostacyclin re-
ceptor [55]. Finally, PPARβ/δ agonists enhance the eﬃcacy
of PPARγ agonists in mediating adipocyte diﬀerentiation in
vitro [56], suggesting that PPARβ/δ agonists may also po-
tentiate the antiﬁbrotic eﬀects of PPARγ agonists discussed
below.
5. PPARγ
PPARγ is expressed in many types of lung cells includ-
ing ﬁbroblasts, ciliated airway epithelial cells and alveolar
type II pneumocytes, alveolar macrophages, T lymphocytes,
and airway smooth muscle cells [57]. Endogenous ligands
of PPARγ include 15-deoxy −Δ12,14-prostaglandin J2 (15d-
PGJ2)[ 58, 59], lysophosphatidic acid [60], and nitrolinoleic
acid [61]. PPARγ can also be activated by synthetic ligands
includingthethiazolidinedione(TZD)classofclinicallyused
insulin-sensitizing drugs [62] including rosiglitizone and pi-
oglitizone, as well as oleanic acid derivatives known as triter-
penoids [63].
The anti-inﬂammatory properties of PPARγ ligands have
been well described [37, 64]. In the lung, PPARγ ligands in-
hibit LPS-induced neutrophilia [65, 66] and allergic airway
inﬂammation and hyperresponsiveness in a mouse model
of asthma [67, 68]. PPARγ ligands also inhibit the release
of proinﬂammatory mediators from airway epithelial cells
and alveolar macrophages [69, 70]. In addition, PPARγ plays
an important role in regulating cellular diﬀerentiation, as
PPARγ ligands promote diﬀerentiation of preadipocyte ﬁ-
broblasts to adipocytes [58, 59, 71].
A number of studies have investigated PPARγ ligands
as potential antiﬁbrotic agents in vivo. Pioglitazone reduced
carbon-tetrachloride-induced hepatic ﬁbrosis in rats, with
decreases in hydroxyl proline content, procollagen I mRNA,
and α-SMA-positive hepatic stellate cells [72]. A similar ef-
fect was observed when ﬁbrosis was induced by a choline-
deﬁcient diet [73, 74]. Rosiglitazone inhibits cardiac ﬁbro-
sis in rats [44] and kidney ﬁbrosis in diabetic mice and rats
[45]. Intriguingly, improvements in renal function have been
noted in patients with type II diabetes who are treated with
TZDs [75, 76].4 PPAR Research
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Figure1:PPARγ ligandspromoteﬁbroblastdiﬀerentiationtoadipocytesandinhibitdiﬀerentiationtomyoﬁbroblasts.Primaryhumanﬁbroblasts
( c e n t e rp a n e l )c a nb ed i ﬀerentiated to adipocyte-like cells (left panel) by treatment with 1 μM 15d-PGJ2 for 8 days. Lipid droplets were
visualized with oil red O staining. Alternatively, incubation with 10 ng/mL TGF-β for 3 days will diﬀerentiate ﬁbroblasts to myoﬁbroblasts
(right panel). α-SMA was detected by immunocytochemistry. Note the long bundles of contractile ﬁbers.
Only a limited amount of data is available on the eﬀects
of PPARγ agonists on lung ﬁbrosis in vivo. Ciglitazone ad-
ministered by nebulization in a mouse model of asthma not
only reduced lung inﬂammation and eosinophilia, but also
reduced basement membrane thickening and collagen depo-
sition associated with airway remodeling, as well as synthesis
of the proﬁbrotic cytokine TGF-β [68]. This eﬀect was abol-
ished by concomitant use of GW9662, an irreversible PPARγ
antagonist.Rosiglitazoneand15d-PGJ2 signiﬁcantlyreduced
mortality, inﬂammation, cellular inﬁltrates, and histological
ﬁbrosis following intratracheal administration of bleomycin
[77]. Studies of the in vivo eﬀects of PPARγ agonists have
been hampered by the fact that unlike PPARα,h o m o z y g o u s
germline deletion of the PPARγ gene results in embryonic
lethality [78]. A conditional knockout mouse, in which exon
2 of the PPARγ gene has been ﬂanked by loxP sites, has been
developed [78], and strategies to inducibly knock out PPARγ
expression in the adult mouse lung prior to ﬁbrotic insult are
being explored in a number of laboratories.
The antiﬁbrotic eﬀects of PPARγ ligands have been stud-
ied in vitro, leading to new insights into their mechanism of
action. As previously discussed, TGF-β drives diﬀerentiation
of lung ﬁbroblasts to myoﬁbroblasts, a key eﬀector cell in ﬁ-
brosis [16, 23, 24]. In contrast, PPARγ ligands diﬀerentiate
ﬁbroblasts to fat-storing adipocytes [58, 59]. This suggests
thatPPARγligandsmayopposetheﬁbrogeniceﬀectsofTGF-
β (Figure 1). We investigated the ability of PPARγ ligands to
counter the proﬁbrotic eﬀects of TGF-β on primary human
lung ﬁbroblasts. Rosiglitazone and 15d-PGJ2 eﬃciently in-
hibited TGF-β-driven diﬀerentiation of human lung ﬁbrob-
lasts to myoﬁbroblasts, with reductions in the expression of
α-SMA (a myoﬁbroblast marker) and production of collagen
[79].
Similar results have been observed in other cell types.
Diﬀerentiation of hepatic stellate cells to a myoﬁbroblast
phenotype is a key step in liver ﬁbrosis [80–82]. PPARγ
agonists suppress proliferation of hepatic stellate cells and
chemotaxis in response to platelet-derived growth fac-
tor (PDGF) [83], and induce hepatocyte growth factor
(HGF), an anti-ﬁbrotic cytokine [84]. PPARγ ligands also
block PDGF-dependent proliferation, prolyl4-hydroxylase
(α) mRNA, and the expression of collagen and α-SMA by
pancreatic stellate cells [85]. Renal cortical ﬁbroblasts treated
with glucose induce myoﬁbroblastic markers. Treatment of
these cells with pioglitizone decreased collagen IV produc-
tion, incorporation of proline, ﬁbronectin production, and
MMP-9 activity as well as reduced secretion of TIMP-1 and
-2 [86, 87].
The molecular mechanisms by which PPARγ ligands in-
hibit myoﬁbroblast diﬀerentiation and eﬀector function are
underinvestigation.BecauseTGF-βappearstobeakeyproﬁ-
brotic cytokine in lung ﬁbrosis [2, 21], several groups have
investigated the ability of PPARγ ligands to interfere with
TGF-β signaling. TGF-β signaling is mediated by the Smad
familyoftranscriptionfactors[21].BindingofTGF-β totype
2T G F - β receptor recruits type 1 TGF-β receptors (TGF-βR-
I), forming a heterotetrameric structure that phosphorylates
Smad2 and Smad3. Smad2 and Smad3 form heteromeric
complexes with Smad4, which translocate to the nucleus
and activate transcription of target genes (Figure 2). In hu-
man hepatic stellate cells, TGF-β causes a time- and dose-
dependent increase in Smad3 phosphorylation, followed by
increased collagen production. Cotreatment with either a
TGF-βR-I kinase inhibitor or the synthetic PPARγ agonist
GW7845 resulted in dose-dependent inhibition of both col-
lagen production and Smad3 phosphorylation [88]. In con-
trast, the natural PPARγ agonist 15d-PGJ2 did not inhibit
nuclear translocation of Smad2/3 complexes in human re-
nal mesangial cells treated with TGF-β.I n s t e a d ,1 5 d - P G J 2
inducedexpressionoftheantiﬁbrotichepatocytegrowthfac-
tor (HGF) via a peroxisome proliferator response element
in the HGF promoter, and upregulated the Smad corepres-
sor TG-interacting factor (TGIF), leading to inhibition of
α-SMA and ﬁbronectin expression [84]. Interestingly, the
same study reported that 15d-PGJ2 did inhibit Smad2/3 nu-
cleartranslocationinratkidneyﬁbroblaststreatedwithTGF-
β, while we have reported that 15d-PGJ2 does not inhibit
TGF-β-stimulatedphosphorylationofSmad2inhumanlungHeather F. Lakatos et al. 5
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Figure 2: The TGF-β signaling pathway. Binding of TGF-β to TGF-β receptor II recruits TGF-β receptor I (TGF-βR-I). The kinase domain
of TGF-βR-I phosphorylates Smad2 and 3, which form a heteromeric complex with Smad4 that translocates into the nucleus where it
activates transcription of target genes. Numbers indicate points in the pathway where PPARγ ligands have been demonstrated to interfere
with TGF-β signaling. (1) GW7845, a PPARγ ligand, inhibited Smad3 phosphorylation in human hepatic stellate cells [88]. (2) 15d-PGJ2
inhibited nuclear translocation of Smad2/3 in rat kidney ﬁbroblasts [84]. (3) In human renal mesangial cells, 15d-PGJ2 induced hepatocyte
growth factor (HGF), which upregulates the Smad corepressor TG-interacting factor (TGIF) [84]. (4) In mouse L929 ﬁbroblasts, 15d-PGJ2
or retinoic acid upregulated the phosphatase and tensin homologue deleted on chromosome 10 (PTEN), leading to repression of TGF-β1
transcription [89].
ﬁbroblasts[79].Itispossible thatinhibition ofmyoﬁbroblast
diﬀerentiation by PPARγ agonists is mediated by diﬀerent
mechanisms in diﬀe r e n tc e l lt y p e s ,o rt h a tn a t u r a la n ds y n -
thetic agonists act by diﬀerent mechanisms.
Another candidate mechanism for inhibition of proﬁ-
brotic eﬀector functions of ﬁbroblasts involves upregulation
of the tumor-suppressor phosphatase and tensin homologue
deleted on chromosome 10 (PTEN). The PTEN promoter
contains a PPRE, and PPARγ ligands upregulate PTEN ex-
pression[90].InvitrostudieshaveshownthatPTENinhibits
ﬁbroblast-myoﬁbroblast diﬀerentiation and expression of α-
SMA and collagen in human and mouse lung ﬁbroblasts
[91], while loss of PTEN activity contributes to the migra-
tory/invasive phenotype of lung ﬁbroblasts isolated from IPF
patients [92]. It has also been reported that PTEN levels are
decreased in the lung tissue of IPF patients, and that PTEN
knockout mice aremore susceptible to bleomycin-induced ﬁ-
brosis [91]. Interestingly, both 15d-PGJ2 and the RXR lig-
and 9-cis-retinoic acid inhibited transcription of the TGF-β1
gene via PTEN upregulation in mouse L929 ﬁbroblasts [89],
providing an additional mechanism by which PPARγ ligands
might interfere directly with the proﬁbrotic eﬀects of TGF-β.
One important consideration is that the eﬀects of PPARγ
ligandsmaynotallbedependentonPPARγ-dependenttran-
scriptional activation. PPARγ-dependent transcriptional re-
pression has been described in adipogensis, but not in my-
oﬁbroblast diﬀerentiation [93, 94]. Additionally, recent re-
ports have suggested that some of the biological eﬀects of
15d-PGJ2 are moderated by a PPARγ-independent mecha-
nism involving modiﬁcation of protein thiols by an elec-
trophilic carbon on the imidazole ring of 15d-PGJ2 [95, 96].
For example, the ability of troglitazone or 15d-PGJ2 to in-
hibit proliferation of hepatic stellate cells was shown to be
PPARγ-independent [97], while 15d-PGJ2 inhibts the pro-
liferation of human breast carcinoma cell lines by covalent
modiﬁcation of the estrogen receptor DNA-binding domain
[98]. We examined the PPARγ dependence of the antiﬁ-
brotic eﬀects of PPARγ ligands on human lung ﬁbroblasts.
Neither the irreversible PPARγ antagonist GW9662 nor a
dominant-negative PPARγ mutant signiﬁcantly blocked the
ability of 15d-PGJ2 to inhibit TGF-β-induced α-SMA ex-
pression, suggesting that this eﬀect of 15d-PGJ2 was largely
PPARγ-independent [79]. However, the antiﬁbrotic eﬀects
of rosiglitizone were rescued signiﬁcantly by the dominant-
negative PPARγ, suggesting that while rosiglitizone was less
eﬀectiveatinhibitingmyoﬁbroblastdiﬀerentiation,theeﬀect
was mostly dependent on PPARγ [79].
6. RETINOID X RECEPTOR
The PPARs must form heterodimers with the retinoid X re-
ceptor (RXR) in order to initiate gene transcription [99].
Therefore, it has been proposed that the anti-inﬂammatory
and antiﬁbrotic functions of PPARs may be addressed or
enhanced by RXR ligands, predominantly the retinoic acids
[100,101].Intheratliver,endogenousandsyntheticretinoic
acids (RA) reduced proliferation of HSCs and production
of collagen I. In addition, all-trans RAs inhibited the syn-
thesis of collagen I/II and ﬁbronectin but did not aﬀect
HSC proliferation [102]. Levels of RXR-α and RXR-β were
decreased in the HSC of rats with cholestatic liver ﬁbro-
sis [103]. In addition, there were decreases in all-trans RA
and 9-cis-RA levels and RA binding to the retinoid receptor
response element (RARE) in ﬁbrotic liver tissue. Similar6 PPAR Research
ﬁndings have been demonstrated in glomerular mesangial
cells where 9-cis-RA induced the antiﬁbrotic growth factor
HGF and inhibited TGF-β-stimulated induction of α-SMA
a n dﬁ b r o n e c t i n[ 104]. Synergistic eﬀects between RXR lig-
ands and PPAR ligands have not yet been reported in lung ﬁ-
broblastsinvitroorinanimalmodelsoflungﬁbrosis,though
this is under investigation.
7. CONCLUSION
Although the role of the PPARs in ﬁbrosing diseases has been
less well studied than their role in regulating inﬂammation,
a number of key results have emerged. PPARγ agonists in-
hibit the diﬀerentiation of lung ﬁbroblasts to myoﬁbroblasts
in vitro, and also inhibit airway remodeling and ﬁbrosis in
animal models [77, 79]. PPARα agonists also attenuated ﬁ-
brosis in the mouse bleomycin model, while PPARα knock-
out mice developed more severe disease [50].
Our understanding of the role of PPARs in lung ﬁbro-
sis is hindered by the relative lack of experiments directly
involving the lung or lung cells. However, progress has also
been made toward determining the role of the PPARs in
ﬁbrosing diseases of the liver, kidney, and pancreas. Hep-
atic stellate cells and pancreatic stellate cells diﬀerentiate to
myoﬁbroblast-like cells under the same stimulus as lung ﬁ-
broblasts, and this diﬀerentiation is inhibited by both nat-
ural and synthetic PPARγ ligands [83–85]. The TZD class of
PPARγ agonistsiseﬀectiveinreducingliver,cardiac,andkid-
ney ﬁbrosis in rats and mice [44, 45, 72]. PPARα agonists,
including the ﬁbrate drugs, have also shown promise in at-
tenuating liver, kidney, and cardiac ﬁbrosis [40, 43, 45].
The mechanisms by which PPAR ligands alter ﬁbrosis are
not well understood, but appear to involve multiple regula-
tory pathways (see Figure 3). Natural and synthetic PPARγ
agonists inhibit TGF-β-driven myoﬁbroblast diﬀerentiation
and activation in hepatic stellate cells, kidney ﬁbroblasts, and
lung ﬁbroblasts. In human hepatic stellate cells, the PPARγ
agonist GW7845 inhibited Smad3 phosphorylation and nu-
clear translocation [88], while a similar result was seen with
15d-PGJ2 in rat kidney ﬁbroblasts [84]. However, 15d-PGJ2
did not alter Smad2 phosphorylation in human lung ﬁbrob-
lasts [79] or human renal mesangial cells, but instead upreg-
ulatedHGFandTGIF[84].Itislikelythattheprecisemecha-
nism of action of PPARγ ligands varies depending on the cell
type and agonist used. A further complication is that PPARγ
agonists appear to have PPARγ-independent eﬀects. Further
studies using pharmaceutical inhibitors of PPARγ or PPARγ
knockoutcelllinesmayproveusefulinfurtherinvestigations.
A very intriguing recent report found that 15d-PGJ2 al-
tered transcriptional activity of the estrogen receptor by co-
valent modiﬁcation of cysteine residues in its zinc ﬁnger
DNA-binding domain [98]. Since cysteine is a ready target of
covalent modiﬁcation by 15d-PGJ2 [95, 96]a n dm a n yt r a n -
scription factors use cysteine-rich zinc ﬁnger DNA-binding
domains,thissuggeststhatonepossiblemechanismbywhich
PPARγ ligands can aﬀect the regulation of cell diﬀerentiation
independently of PPARγ itself is via modiﬁcation of other
transcription factors.
(1) PPARαligandshaveantiﬁbroticeﬀectsinrodentliverand
lungﬁbrosismodels;themechanismisunknownbutmay
involve downregulation of inﬂammation.
(2) PPARβ/δ plays a role in regulating the transition from in-
ﬂammation to normal wound healing.
(3) PPARβ/δ agonists potentiate the antiﬁbrotic activities of
PPARγ agonists.
(4) PPARγ ligands upregulate transcription of genes that op-
pose myoﬁbroblast diﬀerentiation (PTEN).
(5) PPARγ ligands interfere with TGF-β signaling via the
Smad pathway in some cell types.
Figure 3: Key concepts in the regulation of ﬁbrosis by PPARs.
There are less data available on the mechanism of action
of PPARα and β/δ agonists. Although PPARα agonists atten-
uate animal preclinical ﬁbrosis models, studies of the direct
eﬀect of PPARα ligands on myoﬁbroblast activation have not
been reported. Treprostinil inhibition of lung ﬁbroblast pro-
liferation is PPARβ/δ-dependent [55], and PPARβ/δ also ap-
pears to play a role in keratinocyte maturation and function
[53]. It has been hypothesized that ﬁbrosis is a consequence
ofdysregulatedwoundhealingandtissueremodelingfollow-
ing an initial injury [54]. This may provide the mechanistic
link between PPARα and β/δ and ﬁbrosis. Rather than di-
rectly acting on ﬁbroblasts and myoﬁbroblasts, PPARα may
regulate inﬂammation, while PPARβ/δ regulates the transi-
tion from inﬂammation to wound healing [54, 105]. Thus,
PPARα and β/δ agonists may ameliorate ﬁbrosis by altering
the initial inﬂammatory response and the transition to a ﬁ-
brogenic milieu, respectively.
The relationship between the PPARs and ﬁbrosis is likely
to be complex. As discussed above, PPARα and PPARγ are
involved in regulating both inﬂammation and ﬁbrosis, and
some ligands have aﬃnity for more than one PPAR. In ad-
dition, because RXR is the obligate dimerization partner for
all three PPARs, modulating RXR activity may have multiple
overlapping or even conﬂicting eﬀects. A number of useful
tools exist to study these relationships, including highly spe-
ciﬁc synthetic agonists and antagonists, dominant negative
expression constructs, and germline and conditional gene
knockouts. Each of these approaches has potential advan-
tages and drawbacks. In particular, genetic ablation of PPAR
genes will eliminate their function from both inﬂammatory
and repair processes, making it diﬃcult to determine their
role in each process independently. This problem can be ad-
dressed by using multiple complimentary approaches to ex-
amine PPAR function in both normal and abnormal wound
repair and ﬁbrosis.
It must be emphasized that important classes of PPARα
(the ﬁbrate drugs) and PPARγ (TZDs) agonists are currently
available in the clinic. Although the frequency of lung ﬁ-
brosis in the general population is not high, it may be pos-
s i b l et op e r f o r mr e t r o s p e c t i v es t u d i e so fl o n g - t e r mu s e r so f
TZDs and ﬁbrates to determine whether these drugs reduce
the incidence or severity of lung ﬁbrosis and other ﬁbrosing
diseases. More importantly, the clinical availability of theseHeather F. Lakatos et al. 7
drugs means that signiﬁcant results from animal studies of
ﬁbrosis models may be rapidly applied in the clinical set-
ting. Recent advances in drug delivery by inhalation may al-
low delivery of antiﬁbrotic PPAR agonists directly to the site
of ﬁbrosis (as has already been demonstrated with the use
of ciglitazone in a mouse model of airway remodeling [68]),
achieving higher eﬀective doses at the target site with lower
systemic side eﬀects. As most forms of lung ﬁbrosis are re-
fractory to current treatment, the rapid translation of basic
research to bedside practice holds great promise for a patient
population suﬀering from a largely untreatable disease.
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